<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01132313</url>
  </required_header>
  <id_info>
    <org_study_id>1241.21</org_study_id>
    <secondary_id>2009-018197-66</secondary_id>
    <nct_id>NCT01132313</nct_id>
  </id_info>
  <brief_title>Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection</brief_title>
  <official_title>Safety, Antiviral Effect and Pharmacokinetics of BI 207127 in Combination With BI 201335 and With or Without Ribavirin for 4, 16, 24, 28 or 40 Weeks in Patients With Chronic HCV Genotype 1 Infection (Randomized Phase Ib/II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The substances BI 201335 and BI 207127 are being developed for the treatment of chronic
      hepatitis C virus infection. BI 201335 and BI 207127 work by preventing the virus from
      replicating.

      The currently available medications pegylated interferon alfa and ribavirin for hepatitis C
      ca have considerable adverse events in patients and in many cases are not sufficiently
      effective. This is particularly the case in treatment of patients infected with genotype 1 of
      HCV.

      A combination therapy of these new substances without pegylated interferon alfa may be
      associated with fewer adverse events that currently available (pegylated
      interferon-alfa-based) medication and may also provide a treatment option to the large number
      of patients with contraindications or intolerance to pegylated interferon alfa.

      This clinical trial (1241.21) currently consists of 3 distinct studies: Part 1, Part 2 and
      Part 3.

      Part 1 (SOUND-C1) is a 2 armed study as described in experimental arms 1 and 2 below (actual
      enrollment: 56 patients; randomized and treated: 32) Part 2 (SOUND-C2) is a 5 armed study as
      described in experimental arms 3 to 7 below (actual enrollment: 465; randomized and treated:
      362) Part 3 (SOUND-C3) includes 3 arms as described in experimental arms 8 to 10 below (83
      patients randomized and treated)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Rapid Virological Response (RVR)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Part 1: Rapid virological response (RVR), defined as Hepatitis C Virus Ribonucleic acid (HCV RNA) &lt;25IU/mL at Week 4 of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Sustained Virological Response (SVR)</measure>
    <time_frame>From drug administration until 12 weeks after end of treatment, up to 52 weeks</time_frame>
    <description>Part 2: Sustained virological response (SVR), defined as HCV RNA &lt;25 IU/mL and undetectable at 12 weeks after end of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 and 4: Sustained Virological Response (SVR)</measure>
    <time_frame>From drug administration until 12 weeks after end of treatment, up to 36 weeks</time_frame>
    <description>Part 3 and 4: Sustained virological response (SVR) defined as HCV RNA &lt;25IU/mL and undetectable at 12 weeks after end of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Time to Virological Response</measure>
    <time_frame>From drug administration until end of drug administration, up to 4 weeks</time_frame>
    <description>Part 1: Time to virological response, defined as the timepoint of the first measurement of plasma HCV RNA level &lt;25 IU/mL. The percentage of participants who achieved virological response within each time period are displayed for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Time to Virological Response</measure>
    <time_frame>From drug administration until end of drug administration, up to 40 weeks</time_frame>
    <description>Part 2: Time to virological response, defined as the timepoint of the first measurement of plasma HCV RNA level &lt;25 IU/mL. The percentage of participants who achieved virological response within each time period are displayed for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Plasma HCV RNA Level Not Detectable at Week 4</measure>
    <time_frame>4 weeks</time_frame>
    <description>Part 1 and 2: Plasma Hepatitis C Virus Ribonucleic acid (HCV RNA) level not detectable at Week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Sustained Virological Response at 4 and 24 Weeks After End of Treatment</measure>
    <time_frame>4 weeks and 24 weeks after the end of treatment, up to 64 weeks</time_frame>
    <description>Part 2: Sustained virological response at 4 and 24 weeks after end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3 and 4: Plasma HCV RNA Level &lt;25 IU/mL at Week 4 and 12 of Treatment</measure>
    <time_frame>Week 4 and 12</time_frame>
    <description>Part 3 and 4: Plasma Hepatitis C Virus Ribonucleic acid (HCV RNA) level &lt;25 IU/mL at week 4 and 12 of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3 and 4: Sustained Virological Response (SVR) at 4 Weeks After End of Treatment</measure>
    <time_frame>up to 28 weeks</time_frame>
    <description>Part 3 and 4: Sustained virological response (SVR) at 4 weeks after end of treatment</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">488</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 weeks of high dose TID BI 207127 and QD BI 201335 in combination with RBV, Part 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 weeks of low dose three times per day (TID) BI 207127 and once daily (QD) BI 201335 in combination with RBV, Part 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>28 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>28 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>28 weeks of TID BI 207127 and QD BI 201335 without RBV, Part 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127</intervention_name>
    <description>28 weeks, high dose, TID</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335</intervention_name>
    <description>40 weeks, QD</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127</intervention_name>
    <description>4 weeks, low dose TID</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335</intervention_name>
    <description>24 weeks, QD</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>16 weeks, according to label</description>
    <arm_group_label>11</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>28 weeks, according to label</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>28 weeks, according to label</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127</intervention_name>
    <description>40 weeks, high dose, TID</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127</intervention_name>
    <description>24 weeks, very high dose, BID</description>
    <arm_group_label>9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127</intervention_name>
    <description>16 weeks, standard dose, BID</description>
    <arm_group_label>11</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335</intervention_name>
    <description>24 weeks, QD</description>
    <arm_group_label>10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>48 weeks, according to label</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>40 weeks, according to label</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127</intervention_name>
    <description>16 weeks, high dose, TID</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127</intervention_name>
    <description>28 weeks, high dose, TID</description>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335</intervention_name>
    <description>28 weeks, QD</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335</intervention_name>
    <description>16 weeks, QD</description>
    <arm_group_label>11</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>24 weeks, according to label</description>
    <arm_group_label>12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335</intervention_name>
    <description>24 weeks, QD</description>
    <arm_group_label>12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335</intervention_name>
    <description>28 weeks, QD</description>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127</intervention_name>
    <description>24 weeks, standard dose, BID</description>
    <arm_group_label>12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335</intervention_name>
    <description>24 weeks, QD</description>
    <arm_group_label>9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335</intervention_name>
    <description>16 weeks, QD</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127</intervention_name>
    <description>16 weeks, high dose, BID</description>
    <arm_group_label>8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335</intervention_name>
    <description>24 weeks, QD</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>16 weeks, according to label</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>16 weeks, according to label</description>
    <arm_group_label>8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207217</intervention_name>
    <description>28 weeks, high dose BID</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335</intervention_name>
    <description>16 weeks, QD</description>
    <arm_group_label>8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127</intervention_name>
    <description>24 weeks, high dose, TID</description>
    <arm_group_label>10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>48 weeks, according to label</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127</intervention_name>
    <description>4 weeks, high dose, TID</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335</intervention_name>
    <description>28 weeks, QD</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>24 weeks, according to label</description>
    <arm_group_label>9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>24 weeks, according to label</description>
    <arm_group_label>10</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Chronic hepatitis C virus (HCV) infection of genotype (GT) 1

          -  Parts 1-3:Treatment naive to Interferon -alfa (IFN), Pegylated interferon -alfa
             (PegIFN), ribavirin (RBV), and any direct acting antiviral agent for chronic hepatitis
             C

          -  Part 4: Treatment experienced with confirmed prior virological failure to an approved
             dose of PegIFN/RBV (null-response)

          -  HCV RNA &gt;=10,000 IU/mL at screening

          -  Liver biopsy within two years or fibroscan within six months prior to baseline

          -  Liver biopsy within two years or fibroscan within 6 months prior to screening

          -  Age 18-75 years

        Exclusion criteria:

          -  Hepatitis C virus (HCV) infection of mixed genotype

          -  Evidence of liver disease due to causes other than chronic HCV infection

          -  Positive ELISA for human immunodeficiency virus (HIV)

          -  Hepatitis B virus (HBV) infection

          -  Decompensated liver disease or history of decompensated liver disease

          -  Active or suspected malignancy within the last 5 years

          -  Ongoing or historical photosensitivity or recurrent rash

          -  History of alcohol or drug abuse (except cannabis) within the past 12 months

          -  Body mass index (BMI)I &lt;18 or &gt; 35 kg/m2

          -  Usage of any investigational drugs within 30 days prior to enrolment, or 5 half-lives,
             whichever is longer; o the planned usage of an investigational drug during the course
             of the current study

          -  Known hypersensitivity to any ingredient of the study drugs

          -  A condition that is defined as one which in the opinion of the investigator may
             interfere with the patient's capability for participation in the trial or may
             influence the results of the trial

          -  Alpha fetoprotein &gt;100ng/mL at screening; if &gt;20ng/mL and &lt;=100ng/mL, patients can be
             included if there is no evidence of liver cancer in an appropriate imaging study
             within 6 months prior to randomisation

          -  Total bilirubin &gt; 2 mg/dL with ratio of direct/indirect &gt; 1

          -  AST or ALT &gt;5xULN

          -  INR prolonged to &gt;1.7xULN

          -  Requirement for chronic systemic corticosteroids

          -  Received concomitant systemic antiviral, hematopoietic growth factor, or
             immunomodulatory treatment within 30 days prior to enrolment or 5 half-lives,
             whichever is longer

          -  Received silymarin or glycyrrhizin or Sho-saiko-to within 30 days prior to enrolment

          -  Contraindications pertaining to PegIFN or RBV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1241.21.0003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.0006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.0004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.0011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.0013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valparaiso</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.0008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.0019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.0012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.0005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.0007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.0010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.0017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.61002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.61001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.43003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.43002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.33005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.33007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grenoble cédex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.33003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.33001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.33002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.33004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.33008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.33006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vandoeuvre Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Esslingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.64001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Auckland NZ</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.35103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aveiro</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.35104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.35101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.35105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.35102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.40001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.40002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.40003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.34005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.34003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.34004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Majadahonda-Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.34006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.41003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.41006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.41001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.21.41002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>New Zealand</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2010</study_first_submitted>
  <study_first_submitted_qc>May 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2010</study_first_posted>
  <results_first_submitted>October 29, 2015</results_first_submitted>
  <results_first_submitted_qc>December 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 1, 2016</results_first_posted>
  <disposition_first_submitted>November 5, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>November 5, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 18, 2014</disposition_first_posted>
  <last_update_submitted>December 22, 2015</last_update_submitted>
  <last_update_submitted_qc>December 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This trial was conducted in 4 parts, each consisting of randomised, open-label treatments.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1: 400mg DBV and 120mg FDV - 4w</title>
          <description>Part 1: 4 weeks of 400mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. From week 5 to week 24, patients received treatment with FDV 120mg QD in combination with standard of care (SOC) PegIFN/RBV (triple therapy period)</description>
        </group>
        <group group_id="P2">
          <title>Part 1: 600mg DBV and 120mg FDV - 4w</title>
          <description>Part 1: 4 weeks of 600mg Deleobuvir (DBV, BI 207127) tablet three times per day (TID) and 120mg Faldaprevir (FDV, BI 201335) soft gelatin capsule once daily (QD) in combination with Ribavirin (RBV) tablet. From week 5 to week 24, patients received treatment with FDV 120mg QD in combination with SOC PegIFN/RBV (triple therapy period)</description>
        </group>
        <group group_id="P3">
          <title>Part 2: 600mg DBV and 120mg FDV - 16w</title>
          <description>Part 2: 16 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Part 2: 600mg DBV TID and 120mg FDV - 28w</title>
          <description>Part 2: 28 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Part 2: 600mg DBV and 120mg FDV - 40w</title>
          <description>Part 2: 40 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Part 2: 600mg DBV BID and 120mg FDV - 28w</title>
          <description>Part 2: 28 weeks of 600mg Deleobuvir tablet twice a day (BID) and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Part 2: 600mg DBV and 120mg FDV, no RBV - 28w</title>
          <description>Part 2: 28 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD, without RBV. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
        </group>
        <group group_id="P8">
          <title>Part 3: 600mg DBV and 120mg FDV - 16w</title>
          <description>Part 3: 16 weeks of 600mg Deleobuvir tablet BID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
        </group>
        <group group_id="P9">
          <title>Part 3: 800mg DBV and 120mg FDV - 24w</title>
          <description>Part 3: 24 weeks of 800mg Deleobuvir tablet BID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
        </group>
        <group group_id="P10">
          <title>Part 3: 600mg DBV and 120mg FDV - 24w</title>
          <description>Part 3: 24 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
        </group>
        <group group_id="P11">
          <title>Part 4: 600 mg DBV and 120mg FDV - 16w</title>
          <description>Part 4: 16 weeks of 600mg Deleobuvir tablet BID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet.</description>
        </group>
        <group group_id="P12">
          <title>Part 4: 600 mg DBV and 120mg FDV - 24w</title>
          <description>Part 4: 24 weeks of 600mg Deleobuvir tablet BID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="81"/>
                <participants group_id="P4" count="80"/>
                <participants group_id="P5" count="79"/>
                <participants group_id="P6" count="79"/>
                <participants group_id="P7" count="49"/>
                <participants group_id="P8" count="32"/>
                <participants group_id="P9" count="26"/>
                <participants group_id="P10" count="25"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="61"/>
                <participants group_id="P4" count="48"/>
                <participants group_id="P5" count="34"/>
                <participants group_id="P6" count="54"/>
                <participants group_id="P7" count="19"/>
                <participants group_id="P8" count="24"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="32"/>
                <participants group_id="P5" count="45"/>
                <participants group_id="P6" count="25"/>
                <participants group_id="P7" count="30"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="21"/>
                <participants group_id="P10" count="20"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="14"/>
                <participants group_id="P10" count="16"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="19"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of antiviral response</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="21"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set which included all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment regardless of randomisation.</population>
      <group_list>
        <group group_id="B1">
          <title>Part 1: 400mg DBV and 120mg FDV - 4w</title>
          <description>Part 1: 4 weeks of 400mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. From week 5 to week 24, patients received treatment with FDV 120mg QD in combination with standard of care (SOC) PegIFN/RBV (triple therapy period)</description>
        </group>
        <group group_id="B2">
          <title>Part 1: 600mg DBV and 120mg FDV - 4w</title>
          <description>Part 1: 4 weeks of 600mg Deleobuvir (DBV, BI 207127) tablet three times per day (TID) and 120mg Faldaprevir (FDV, BI 201335) soft gelatin capsule once daily (QD) in combination with Ribavirin (RBV) tablet. From week 5 to week 24, patients received treatment with FDV 120mg QD in combination with SOC PegIFN/RBV (triple therapy period)</description>
        </group>
        <group group_id="B3">
          <title>Part 2: 600mg DBV and 120mg FDV - 16w</title>
          <description>Part 2: 16 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Part 2: 600mg DBV TID and 120mg FDV - 28w</title>
          <description>Part 2: 28 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Part 2: 600mg DBV and 120mg FDV - 40w</title>
          <description>Part 2: 40 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Part 2: 600mg DBV BID and 120mg FDV - 28w</title>
          <description>Part 2: 28 weeks of 600mg Deleobuvir tablet twice a day (BID) and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Part 2: 600mg DBV and 120mg FDV, no RBV - 28w</title>
          <description>Part 2: 28 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD, without RBV. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
        </group>
        <group group_id="B8">
          <title>Part 3: 600mg DBV and 120mg FDV - 16w</title>
          <description>Part 3: 16 weeks of 600mg Deleobuvir tablet BID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
        </group>
        <group group_id="B9">
          <title>Part 3: 800mg DBV and 120mg FDV - 24w</title>
          <description>Part 3: 24 weeks of 800mg Deleobuvir tablet BID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
        </group>
        <group group_id="B10">
          <title>Part 3: 600mg DBV and 120mg FDV - 24w</title>
          <description>Part 3: 24 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
        </group>
        <group group_id="B11">
          <title>Part 4: 600 mg DBV and 120mg FDV - 16w</title>
          <description>Part 4: 16 weeks of 600mg Deleobuvir tablet BID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet.</description>
        </group>
        <group group_id="B12">
          <title>Part 4: 600 mg DBV and 120mg FDV - 24w</title>
          <description>Part 4: 24 weeks of 600mg Deleobuvir tablet BID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet.</description>
        </group>
        <group group_id="B13">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="81"/>
            <count group_id="B4" value="80"/>
            <count group_id="B5" value="77"/>
            <count group_id="B6" value="78"/>
            <count group_id="B7" value="46"/>
            <count group_id="B8" value="32"/>
            <count group_id="B9" value="26"/>
            <count group_id="B10" value="25"/>
            <count group_id="B11" value="1"/>
            <count group_id="B12" value="2"/>
            <count group_id="B13" value="480"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.8" spread="10.0"/>
                    <measurement group_id="B2" value="50.8" spread="11.5"/>
                    <measurement group_id="B3" value="48.6" spread="11.3"/>
                    <measurement group_id="B4" value="47.3" spread="11.2"/>
                    <measurement group_id="B5" value="48.9" spread="10.7"/>
                    <measurement group_id="B6" value="47.9" spread="11.1"/>
                    <measurement group_id="B7" value="45.3" spread="13.0"/>
                    <measurement group_id="B8" value="48.9" spread="11.8"/>
                    <measurement group_id="B9" value="47.2" spread="13.4"/>
                    <measurement group_id="B10" value="46.5" spread="12.5"/>
                    <measurement group_id="B11" value="59.0">Not calculable due to only one patient in treatment group</measurement>
                    <measurement group_id="B12" value="52.5" spread="4.9"/>
                    <measurement group_id="B13" value="48.1" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="37"/>
                    <measurement group_id="B7" value="22"/>
                    <measurement group_id="B8" value="20"/>
                    <measurement group_id="B9" value="11"/>
                    <measurement group_id="B10" value="11"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="36"/>
                    <measurement group_id="B6" value="41"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="15"/>
                    <measurement group_id="B10" value="14"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Rapid Virological Response (RVR)</title>
        <description>Part 1: Rapid virological response (RVR), defined as Hepatitis C Virus Ribonucleic acid (HCV RNA) &lt;25IU/mL at Week 4 of treatment</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS which included all randomised patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 400mg DBV and 120mg FDV - 4w</title>
            <description>Part 1: 4 weeks of 400mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. From week 5 to week 24, patients received treatment with FDV 120mg QD in combination with standard of care (SOC) PegIFN/RBV (triple therapy period)</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 600mg DBV and 120mg FDV - 4w</title>
            <description>Part 1: 4 weeks of 600mg Deleobuvir (DBV, BI 207127) tablet three times per day (TID) and 120mg Faldaprevir (FDV, BI 201335) soft gelatin capsule once daily (QD) in combination with Ribavirin (RBV) tablet. From week 5 to week 24, patients received treatment with FDV 120mg QD in combination with SOC PegIFN/RBV (triple therapy period)</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Rapid Virological Response (RVR)</title>
          <description>Part 1: Rapid virological response (RVR), defined as Hepatitis C Virus Ribonucleic acid (HCV RNA) &lt;25IU/mL at Week 4 of treatment</description>
          <population>FAS which included all randomised patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3" lower_limit="47.6" upper_limit="89.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="84.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Sustained Virological Response (SVR)</title>
        <description>Part 2: Sustained virological response (SVR), defined as HCV RNA &lt;25 IU/mL and undetectable at 12 weeks after end of treatment</description>
        <time_frame>From drug administration until 12 weeks after end of treatment, up to 52 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: 600mg DBV and 120mg FDV - 16w</title>
            <description>Part 2: 16 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: 600mg DBV TID and 120mg FDV - 28w</title>
            <description>Part 2: 28 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: 600mg DBV and 120mg FDV - 40w</title>
            <description>Part 2: 40 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: 600mg DBV BID and 120mg FDV - 28w</title>
            <description>Part 2: 28 weeks of 600mg Deleobuvir tablet twice a day (BID) and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: 600mg DBV and 120mg FDV, no RBV - 28w</title>
            <description>Part 2: 28 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD, without RBV. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Sustained Virological Response (SVR)</title>
          <description>Part 2: Sustained virological response (SVR), defined as HCV RNA &lt;25 IU/mL and undetectable at 12 weeks after end of treatment</description>
          <population>FAS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="78"/>
                <count group_id="O5" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.3"/>
                    <measurement group_id="O2" value="58.8"/>
                    <measurement group_id="O3" value="51.9"/>
                    <measurement group_id="O4" value="69.2"/>
                    <measurement group_id="O5" value="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3 and 4: Sustained Virological Response (SVR)</title>
        <description>Part 3 and 4: Sustained virological response (SVR) defined as HCV RNA &lt;25IU/mL and undetectable at 12 weeks after end of treatment</description>
        <time_frame>From drug administration until 12 weeks after end of treatment, up to 36 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3: 600mg DBV and 120mg FDV - 16w</title>
            <description>Part 3: 16 weeks of 600mg Deleobuvir tablet BID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part 3: 800mg DBV and 120mg FDV - 24w</title>
            <description>Part 3: 24 weeks of 800mg Deleobuvir tablet BID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part 3: 600mg DBV and 120mg FDV - 24w</title>
            <description>Part 3: 24 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Part 4: 600 mg DBV and 120mg FDV - 16w</title>
            <description>Part 4: 16 weeks of 600mg Deleobuvir tablet BID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet.</description>
          </group>
          <group group_id="O5">
            <title>Part 4: 600 mg DBV and 120mg FDV - 24w</title>
            <description>Part 4: 24 weeks of 600mg Deleobuvir tablet BID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 and 4: Sustained Virological Response (SVR)</title>
          <description>Part 3 and 4: Sustained virological response (SVR) defined as HCV RNA &lt;25IU/mL and undetectable at 12 weeks after end of treatment</description>
          <population>FAS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.6" lower_limit="46.8" upper_limit="81.4"/>
                    <measurement group_id="O2" value="19.2" lower_limit="6.6" upper_limit="39.4"/>
                    <measurement group_id="O3" value="12.0" lower_limit="2.5" upper_limit="31.2"/>
                    <measurement group_id="O4" value="NA">The study was stopped before data were collected from the participants in Part 4</measurement>
                    <measurement group_id="O5" value="NA">The study was stopped before data were collected from the participants in Part 4</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Time to Virological Response</title>
        <description>Part 1: Time to virological response, defined as the timepoint of the first measurement of plasma HCV RNA level &lt;25 IU/mL. The percentage of participants who achieved virological response within each time period are displayed for this outcome measure.</description>
        <time_frame>From drug administration until end of drug administration, up to 4 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 400mg DBV and 120mg FDV - 4w</title>
            <description>Part 1: 4 weeks of 400mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. From week 5 to week 24, patients received treatment with FDV 120mg QD in combination with standard of care (SOC) PegIFN/RBV (triple therapy period)</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 600mg DBV and 120mg FDV - 4w</title>
            <description>Part 1: 4 weeks of 600mg Deleobuvir (DBV, BI 207127) tablet three times per day (TID) and 120mg Faldaprevir (FDV, BI 201335) soft gelatin capsule once daily (QD) in combination with Ribavirin (RBV) tablet. From week 5 to week 24, patients received treatment with FDV 120mg QD in combination with SOC PegIFN/RBV (triple therapy period)</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Time to Virological Response</title>
          <description>Part 1: Time to virological response, defined as the timepoint of the first measurement of plasma HCV RNA level &lt;25 IU/mL. The percentage of participants who achieved virological response within each time period are displayed for this outcome measure.</description>
          <population>FAS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;= 2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;= 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;= 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3"/>
                    <measurement group_id="O2" value="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;= 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;= 16 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;= 28 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;= 32 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;= 40 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 40 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Time to Virological Response</title>
        <description>Part 2: Time to virological response, defined as the timepoint of the first measurement of plasma HCV RNA level &lt;25 IU/mL. The percentage of participants who achieved virological response within each time period are displayed for this outcome measure.</description>
        <time_frame>From drug administration until end of drug administration, up to 40 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: 600mg DBV and 120mg FDV - 16w</title>
            <description>Part 2: 16 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: 600mg DBV TID and 120mg FDV - 28w</title>
            <description>Part 2: 28 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: 600mg DBV and 120mg FDV - 40w</title>
            <description>Part 2: 40 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: 600mg DBV BID and 120mg FDV - 28w</title>
            <description>Part 2: 28 weeks of 600mg Deleobuvir tablet twice a day (BID) and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: 600mg DBV and 120mg FDV, no RBV - 28w</title>
            <description>Part 2: 28 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD, without RBV. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Time to Virological Response</title>
          <description>Part 2: Time to virological response, defined as the timepoint of the first measurement of plasma HCV RNA level &lt;25 IU/mL. The percentage of participants who achieved virological response within each time period are displayed for this outcome measure.</description>
          <population>FAS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="78"/>
                <count group_id="O5" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N=81, 80, 77, 78, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8(N=75, 72, 72, 75, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="7.7"/>
                    <measurement group_id="O3" value="1.4"/>
                    <measurement group_id="O4" value="2.6"/>
                    <measurement group_id="O5" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (N=62, 61, 63, 60, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4"/>
                    <measurement group_id="O2" value="20.7"/>
                    <measurement group_id="O3" value="9.9"/>
                    <measurement group_id="O4" value="22.1"/>
                    <measurement group_id="O5" value="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (N=29, 32, 27, 32, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5"/>
                    <measurement group_id="O2" value="55.5"/>
                    <measurement group_id="O3" value="59.4"/>
                    <measurement group_id="O4" value="57.7"/>
                    <measurement group_id="O5" value="48.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (N=16, 12, 13, 18, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.8"/>
                    <measurement group_id="O2" value="83.3"/>
                    <measurement group_id="O3" value="80.5"/>
                    <measurement group_id="O4" value="76.2"/>
                    <measurement group_id="O5" value="70.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (N=9, 8, 9, 11, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.1"/>
                    <measurement group_id="O2" value="88.9"/>
                    <measurement group_id="O3" value="85.1"/>
                    <measurement group_id="O4" value="85.5"/>
                    <measurement group_id="O5" value="78.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 (N=9, 7, 8, 11, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.1"/>
                    <measurement group_id="O2" value="90.3"/>
                    <measurement group_id="O3" value="86.8"/>
                    <measurement group_id="O4" value="85.5"/>
                    <measurement group_id="O5" value="78.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113 (N=9, 7, 8, 11, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.1"/>
                    <measurement group_id="O2" value="90.3"/>
                    <measurement group_id="O3" value="86.8"/>
                    <measurement group_id="O4" value="85.5"/>
                    <measurement group_id="O5" value="80.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141 (N=9, 7, 8, 11, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.1"/>
                    <measurement group_id="O2" value="90.3"/>
                    <measurement group_id="O3" value="86.8"/>
                    <measurement group_id="O4" value="85.5"/>
                    <measurement group_id="O5" value="80.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169 (N=9, 7, 8, 11, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.1"/>
                    <measurement group_id="O2" value="90.3"/>
                    <measurement group_id="O3" value="86.8"/>
                    <measurement group_id="O4" value="85.5"/>
                    <measurement group_id="O5" value="80.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 197 (N=9, 7, 8, 11, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.1"/>
                    <measurement group_id="O2" value="90.3"/>
                    <measurement group_id="O3" value="86.8"/>
                    <measurement group_id="O4" value="85.5"/>
                    <measurement group_id="O5" value="80.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1 and 2: Plasma HCV RNA Level Not Detectable at Week 4</title>
        <description>Part 1 and 2: Plasma Hepatitis C Virus Ribonucleic acid (HCV RNA) level not detectable at Week 4</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 400mg DBV and 120mg FDV - 4w</title>
            <description>Part 1: 4 weeks of 400mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. From week 5 to week 24, patients received treatment with FDV 120mg QD in combination with standard of care (SOC) PegIFN/RBV (triple therapy period)</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 600mg DBV and 120mg FDV - 4w</title>
            <description>Part 1: 4 weeks of 600mg Deleobuvir (DBV, BI 207127) tablet three times per day (TID) and 120mg Faldaprevir (FDV, BI 201335) soft gelatin capsule once daily (QD) in combination with Ribavirin (RBV) tablet. From week 5 to week 24, patients received treatment with FDV 120mg QD in combination with SOC PegIFN/RBV (triple therapy period)</description>
          </group>
          <group group_id="O3">
            <title>Part 2: 600mg DBV and 120mg FDV - 16w</title>
            <description>Part 2: 16 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: 600mg DBV TID and 120mg FDV - 28w</title>
            <description>Part 2: 28 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: 600mg DBV and 120mg FDV - 40w</title>
            <description>Part 2: 40 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: 600mg DBV BID and 120mg FDV - 28w</title>
            <description>Part 2: 28 weeks of 600mg Deleobuvir tablet twice a day (BID) and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Part 2: 600mg DBV and 120mg FDV, no RBV - 28w</title>
            <description>Part 2: 28 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD, without RBV. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 and 2: Plasma HCV RNA Level Not Detectable at Week 4</title>
          <description>Part 1 and 2: Plasma Hepatitis C Virus Ribonucleic acid (HCV RNA) level not detectable at Week 4</description>
          <population>FAS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="77"/>
                <count group_id="O6" value="78"/>
                <count group_id="O7" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="70.6"/>
                    <measurement group_id="O3" value="65.4"/>
                    <measurement group_id="O4" value="60.0"/>
                    <measurement group_id="O5" value="63.6"/>
                    <measurement group_id="O6" value="56.4"/>
                    <measurement group_id="O7" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Sustained Virological Response at 4 and 24 Weeks After End of Treatment</title>
        <description>Part 2: Sustained virological response at 4 and 24 weeks after end of treatment</description>
        <time_frame>4 weeks and 24 weeks after the end of treatment, up to 64 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: 600mg DBV and 120mg FDV - 16w</title>
            <description>Part 2: 16 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: 600mg DBV TID and 120mg FDV - 28w</title>
            <description>Part 2: 28 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: 600mg DBV and 120mg FDV - 40w</title>
            <description>Part 2: 40 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: 600mg DBV BID and 120mg FDV - 28w</title>
            <description>Part 2: 28 weeks of 600mg Deleobuvir tablet twice a day (BID) and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: 600mg DBV and 120mg FDV, no RBV - 28w</title>
            <description>Part 2: 28 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD, without RBV. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Sustained Virological Response at 4 and 24 Weeks After End of Treatment</title>
          <description>Part 2: Sustained virological response at 4 and 24 weeks after end of treatment</description>
          <population>FAS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="78"/>
                <count group_id="O5" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5"/>
                    <measurement group_id="O2" value="62.5"/>
                    <measurement group_id="O3" value="54.5"/>
                    <measurement group_id="O4" value="69.2"/>
                    <measurement group_id="O5" value="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.0"/>
                    <measurement group_id="O2" value="58.8"/>
                    <measurement group_id="O3" value="49.4"/>
                    <measurement group_id="O4" value="69.2"/>
                    <measurement group_id="O5" value="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 3 and 4: Plasma HCV RNA Level &lt;25 IU/mL at Week 4 and 12 of Treatment</title>
        <description>Part 3 and 4: Plasma Hepatitis C Virus Ribonucleic acid (HCV RNA) level &lt;25 IU/mL at week 4 and 12 of treatment</description>
        <time_frame>Week 4 and 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3: 600mg DBV and 120mg FDV - 16w</title>
            <description>Part 3: 16 weeks of 600mg Deleobuvir tablet BID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part 3: 800mg DBV and 120mg FDV - 24w</title>
            <description>Part 3: 24 weeks of 800mg Deleobuvir tablet BID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part 3: 600mg DBV and 120mg FDV - 24w</title>
            <description>Part 3: 24 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Part 4: 600 mg DBV and 120mg FDV - 16w</title>
            <description>Part 4: 16 weeks of 600mg Deleobuvir tablet BID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet.</description>
          </group>
          <group group_id="O5">
            <title>Part 4: 600 mg DBV and 120mg FDV - 24w</title>
            <description>Part 4: 24 weeks of 600mg Deleobuvir tablet BID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 and 4: Plasma HCV RNA Level &lt;25 IU/mL at Week 4 and 12 of Treatment</title>
          <description>Part 3 and 4: Plasma Hepatitis C Virus Ribonucleic acid (HCV RNA) level &lt;25 IU/mL at week 4 and 12 of treatment</description>
          <population>FAS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="26.9"/>
                    <measurement group_id="O3" value="32.0"/>
                    <measurement group_id="O4" value="NA">The study was stopped before data were collected from the participants in Part 4</measurement>
                    <measurement group_id="O5" value="NA">The study was stopped before data were collected from the participants in Part 4</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 3 and 4: Sustained Virological Response (SVR) at 4 Weeks After End of Treatment</title>
        <description>Part 3 and 4: Sustained virological response (SVR) at 4 weeks after end of treatment</description>
        <time_frame>up to 28 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3: 600mg DBV and 120mg FDV - 16w</title>
            <description>Part 3: 16 weeks of 600mg Deleobuvir tablet BID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part 3: 800mg DBV and 120mg FDV - 24w</title>
            <description>Part 3: 24 weeks of 800mg Deleobuvir tablet BID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part 3: 600mg DBV and 120mg FDV - 24w</title>
            <description>Part 3: 24 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Part 4: 600 mg DBV and 120mg FDV - 16w</title>
            <description>Part 4: 16 weeks of 600mg Deleobuvir tablet BID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet.</description>
          </group>
          <group group_id="O5">
            <title>Part 4: 600 mg DBV and 120mg FDV - 24w</title>
            <description>Part 4: 24 weeks of 600mg Deleobuvir tablet BID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 and 4: Sustained Virological Response (SVR) at 4 Weeks After End of Treatment</title>
          <description>Part 3 and 4: Sustained virological response (SVR) at 4 weeks after end of treatment</description>
          <population>FAS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="56.6" upper_limit="88.5"/>
                    <measurement group_id="O2" value="19.2" lower_limit="6.6" upper_limit="39.4"/>
                    <measurement group_id="O3" value="12.0" lower_limit="2.5" upper_limit="31.2"/>
                    <measurement group_id="O4" value="NA">The study was stopped before data were collected from the participants in Part 4</measurement>
                    <measurement group_id="O5" value="NA">The study was stopped before data were collected from the participants in Part 4</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration until 30 days after last drug administration for parts 1, 2 and 4 and until 28 days after last drug administration for part 3, up to 361 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Part 1: 400mg DBV and 120mg FDV - 4w</title>
          <description>Part 1: 4 weeks of 400mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. From week 5 to week 24, patients received treatment with FDV 120mg QD in combination with standard of care (SOC) PegIFN/RBV (triple therapy period)</description>
        </group>
        <group group_id="E2">
          <title>Part 1: 600mg DBV and 120mg FDV - 4w</title>
          <description>Part 1: 4 weeks of 600mg Deleobuvir (DBV, BI 207127) tablet three times per day (TID) and 120mg Faldaprevir (FDV, BI 201335) soft gelatin capsule once daily (QD) in combination with Ribavirin (RBV) tablet. From week 5 to week 24, patients received treatment with FDV 120mg QD in combination with SOC PegIFN/RBV (triple therapy period)</description>
        </group>
        <group group_id="E3">
          <title>Part 2: 600mg DBV and 120mg FDV - 16w</title>
          <description>Part 2: 16 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Part 2: 600mg DBV TID and 120mg FDV - 28w</title>
          <description>Part 2: 28 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Part 2: 600mg DBV and 120mg FDV - 40w</title>
          <description>Part 2: 40 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Part 2: 600mg DBV BID and 120mg FDV - 28w</title>
          <description>Part 2: 28 weeks of 600mg Deleobuvir tablet twice a day (BID) and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
        </group>
        <group group_id="E7">
          <title>Part 2: 600mg DBV and 120mg FDV, no RBV - 28w</title>
          <description>Part 2: 28 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD, without RBV. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
        </group>
        <group group_id="E8">
          <title>Part 3: 600mg DBV and 120mg FDV - 16w</title>
          <description>Part 3: 16 weeks of 600mg Deleobuvir tablet BID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
        </group>
        <group group_id="E9">
          <title>Part 3: 800mg DBV and 120mg FDV - 24w</title>
          <description>Part 3: 24 weeks of 800mg Deleobuvir tablet BID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
        </group>
        <group group_id="E10">
          <title>Part 3: 600mg DBV and 120mg FDV - 24w</title>
          <description>Part 3: 24 weeks of 600mg Deleobuvir tablet TID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet. Patients who discontinued their assigned treatment early due to lack of antiviral activity could receive additional treatment with PegIFN/RBV for up to 24 weeks.</description>
        </group>
        <group group_id="E11">
          <title>Part 4: 600 mg DBV and 120mg FDV - 16w</title>
          <description>Part 4: 16 weeks of 600mg Deleobuvir tablet BID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet.</description>
        </group>
        <group group_id="E12">
          <title>Part 4: 600 mg DBV and 120mg FDV - 24w</title>
          <description>Part 4: 24 weeks of 600mg Deleobuvir tablet BID and 120mg Faldaprevir soft gelatin capsule QD in combination with RBV tablet.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis pharyngeal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident at work</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Erythema nodosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="71" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="74" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="73" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="43" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="30" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="26" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="25" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Ocular icterus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="29" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lip dry</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="41" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="39" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="26" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="16" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="18" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rash papulosquamous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were only 3 patients entered in part 4 of the trial, therefore no formal analyses of efficacy data were performed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

